Brentuximab Vedotin as Maintenance After Transplant Helps Patients with Hodgkin Lymphoma Avoid Disease Progression

December 7, 2014 8:03 PM

3 0

Patients with relapsed and difficult-to-treat Hodgkin lymphoma who received brentuximab vedotin (Adcetris) following treatment with high-dose chemotherapy and stem cell transplant had an unprecedented 50% higher likelihood of continuing to experience progression-free survival (PFS) at 2 years. This is particularly meaningful because most patients in this population who haven’t experienced relapse 2 years after transplant are cured.

The study’s lead author, Craig Moskowitz, MD, of Memorial Sloan Kettering Cancer Center, reported those results from the phase III, placebo-controlled AETHERA trial at the 2014 ASH Annual Meeting.

Read more

To category page

Loading...